RealTime Dynamix™: Hyperkalemia Q2 2017

With the introduction of Relypsa’s Veltassa in the beginning of 2016 and new competitors such as AstraZeneca/ZS Pharma’s ZS-9 potentially coming into play, RealTime Dynamix: Hyperkalemia provides a detailed and timely look at how the hyperkalemia market is evolving with these new therapeutic options.

Click the button below to view highlights from the cardiology and nephrology perspective reports:

RTD: Hyperkalemia Nephrology & Cardiology

2017-06-20T14:06:36+00:00